Category: Drug Discovery
Global Drug Discovery
-
Compound Management
... CAGR of 16.8% over the analysis period 2024-2030. Compound Management Instruments, one of the segments analyzed in the report, is expected to record a 17.1% CAGR and reach US$752.6 Million by the end of the ... Read More
-
Systemic Lupus Erythematosus (Sle) Drugs
... Million by 2030, growing at a CAGR of 6.4% over the analysis period 2024-2030. The U.S. Market is Estimated at US$68.0 Million While China is Forecast to Grow at 6.1% CAGR The Systemic Lupus Erythematosus ... Read More
-
Pneumonia Therapeutics
... CAGR of 6.7% over the analysis period 2024-2030. Pneumonia Drugs, one of the segments analyzed in the report, is expected to record a 2.6% CAGR and reach US$6.8 Billion by the end of the analysis ... Read More
-
Liver Cancer Drugs
... at a CAGR of 18.4% over the analysis period 2024-2030. Targeted Drug Therapy, one of the segments analyzed in the report, is expected to record a 18.4% CAGR and reach US$5.1 Billion by the end ... Read More
-
Irritable Bowel Syndrome (IBS) Therapeutics
... Billion by 2030, growing at a CAGR of 7.1% over the analysis period 2024-2030. IBS-D Therapeutics, one of the segments analyzed in the report, is expected to record a 6.9% CAGR and reach US$1.9 Billion ... Read More
-
Narcolepsy Therapeutics
... CAGR of 7.1% over the analysis period 2024-2030. Narcolepsy with Cataplexy Therapeutics, one of the segments analyzed in the report, is expected to record a 6.8% CAGR and reach US$1.9 Billion by the end of ... Read More
-
Apoptosis
... 4.6% over the analysis period 2024-2030. Apoptosis Assay Kits, one of the segments analyzed in the report, is expected to record a 4.3% CAGR and reach US$3.9 Billion by the end of the analysis period. ... Read More
-
Anemia Drugs
... CAGR of 4.1% over the analysis period 2024-2030. Iron Deficiency Anemia Drugs, one of the segments analyzed in the report, is expected to record a 5.1% CAGR and reach US$7.4 Billion by the end of ... Read More
-
Peripheral Arterial Disease (PAD) Therapeutics
... Billion by 2030, growing at a CAGR of 6.9% over the analysis period 2024-2030. Peripheral Stents, one of the segments analyzed in the report, is expected to record a 6.7% CAGR and reach US$1.8 Billion ... Read More
-
Gout Therapeutics
... CAGR of 13.4% over the analysis period 2024-2030. NSAIDs, one of the segments analyzed in the report, is expected to record a 13.2% CAGR and reach US$4.7 Billion by the end of the analysis period. ... Read More
-
Drug Discovery Informatics
... at a CAGR of 9.6% over the analysis period 2024-2030. Drug Discovery Informatics Software, one of the segments analyzed in the report, is expected to record a 8.9% CAGR and reach US$3.4 Billion by the ... Read More
-
Desmopressin
... 5.6% over the analysis period 2024-2030. Injectable Solution Form, one of the segments analyzed in the report, is expected to record a 6.2% CAGR and reach US$866.1 Million by the end of the analysis period. ... Read More
-
Chlamydia Infection Diagnostics and Therapeutics
... Billion by 2030, growing at a CAGR of 4.8% over the analysis period 2024-2030. Chlamydia Infection Diagnostics, one of the segments analyzed in the report, is expected to record a 5.1% CAGR and reach US$1.6 ... Read More
-
Bipolar Disorder Therapeutics
... at a CAGR of 3.4% over the analysis period 2024-2030. Antipsychotic Drugs, one of the segments analyzed in the report, is expected to record a 3.3% CAGR and reach US$3.5 Billion by the end of ... Read More
-
Acute Myeloid Leukemia (AML) Therapeutics
... Billion by 2030, growing at a CAGR of 13.3% over the analysis period 2024-2030. Cytarabine, one of the segments analyzed in the report, is expected to record a 15.3% CAGR and reach US$592.7 Million by ... Read More
-
Chiral Technology
... CAGR of 3.6% over the analysis period 2024-2030. Intermediates, one of the segments analyzed in the report, is expected to record a 3.4% CAGR and reach US$8.2 Billion by the end of the analysis period. ... Read More
-
Amyotrophic Lateral Sclerosis
... at a CAGR of 19.4% over the analysis period 2024-2030. The U.S. Market is Estimated at US$345.9 Million While China is Forecast to Grow at 18.4% CAGR The Amyotrophic Lateral Sclerosis market in the U.S. ... Read More
-
Colorectal Cancer Therapeutics
... at a CAGR of 6.5% over the analysis period 2024-2030. Targeted Therapy, one of the segments analyzed in the report, is expected to record a 7.1% CAGR and reach US$14.9 Billion by the end of ... Read More
-
Critical Care Therapeutics
... at a CAGR of 5.7% over the analysis period 2024-2030. Albumin, one of the segments analyzed in the report, is expected to record a 7.0% CAGR and reach US$3.7 Billion by the end of the ... Read More
-
Life Science Analytics Market by Type (Descriptive, Prescriptive, Predictive), Service (Analytics), Application (Drug Discovery, Trials, RWE, Access, Sales & marketing, Drug Safety), End User (Pharma, Medical Device), & Region - Global Forecast to 2029
... grow as a result of the heterogenity & complexity of big data in life sciences, surging demand for technologically advanced analytical solutions for various applications across the industry, such as, research & development, commercialization (market ... Read More
-
Acute Heart Failure (AHF) Therapeutics
... Billion by 2030, growing at a CAGR of 21.0% over the analysis period 2024-2030. Cardiac Glycosides, one of the segments analyzed in the report, is expected to record a 21.5% CAGR and reach US$762.4 Million ... Read More
-
Biosimulation Technology
... CAGR of 15.6% over the analysis period 2024-2030. Biosimulation Software, one of the segments analyzed in the report, is expected to record a 14.8% CAGR and reach US$5.7 Billion by the end of the analysis ... Read More
-
Acute Coronary Syndrome
... at a CAGR of 10.5% over the analysis period 2024-2030. The U.S. Market is Estimated at US$2.6 Billion While China is Forecast to Grow at 16.2% CAGR The Acute Coronary Syndrome market in the U.S. ... Read More
-
High Content Screening (HCS)
... 2030, growing at a CAGR of 9.2% over the analysis period 2024-2030. HCS Instruments, one of the segments analyzed in the report, is expected to record a 9.4% CAGR and reach US$1.0 Billion by the ... Read More
-
Fibromyalgia Therapeutics
... CAGR of 2.9% over the analysis period 2024-2030. Antiepileptics, one of the segments analyzed in the report, is expected to record a 2.8% CAGR and reach US$2.1 Billion by the end of the analysis period. ... Read More
Research Assistance
